Investigators: Most data on drugs never available

“Regardless of the cause, publication bias harms the public good by impairing
the ability of clinicians and patients to make informed clinical decisions, and
the ability of scientists to design safer and more efficient trials based on
past findings,” the authors wrote. “Publication bias can thus be considered a
form of scientific misconduct.” …

Continue reading

Top 10 mistakes biotechs make (and how to avoid them)

“When the FDA says ‘we think you ought to consider’ something, that should not
be viewed as a suggestion, but as a mandate,” he explains. “Companies are
foolish if they don’t follow what the FDA has suggested.” A biotech takes on
significant and unnecessary risk if it doesn’t follow an FDA suggestion or
proactively address the FDA’s concerns. …

Continue reading